Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Rating of "Moderate Buy" by Analysts

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen ratings firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $8.4444.

A number of research firms have weighed in on ALLO. Wall Street Zen downgraded Allogene Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, October 12th. JMP Securities restated a "market perform" rating on shares of Allogene Therapeutics in a research report on Monday, August 4th. JPMorgan Chase & Co. restated an "underweight" rating on shares of Allogene Therapeutics in a research report on Friday, October 10th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Allogene Therapeutics in a research report on Friday.

Insider Activity

In related news, CFO Geoffrey M. Parker sold 36,744 shares of Allogene Therapeutics stock in a transaction on Tuesday, October 21st. The stock was sold at an average price of $1.26, for a total value of $46,297.44. Following the transaction, the chief financial officer directly owned 1,276,796 shares in the company, valued at $1,608,762.96. The trade was a 2.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 13.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Allogene Therapeutics

A number of hedge funds have recently modified their holdings of ALLO. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Allogene Therapeutics in the 1st quarter worth $28,000. Moloney Securities Asset Management LLC acquired a new position in shares of Allogene Therapeutics in the 1st quarter worth $431,000. Y Intercept Hong Kong Ltd acquired a new stake in Allogene Therapeutics during the 1st quarter valued at $64,000. GSA Capital Partners LLP acquired a new stake in Allogene Therapeutics during the 1st quarter valued at $706,000. Finally, Deutsche Bank AG raised its stake in Allogene Therapeutics by 1,416.7% during the 1st quarter. Deutsche Bank AG now owns 99,544 shares of the company's stock valued at $145,000 after purchasing an additional 92,981 shares during the period. 83.63% of the stock is currently owned by institutional investors and hedge funds.

Allogene Therapeutics Price Performance

ALLO opened at $1.20 on Friday. The company has a market capitalization of $266.26 million, a price-to-earnings ratio of -1.08 and a beta of 0.43. Allogene Therapeutics has a 1-year low of $0.86 and a 1-year high of $3.78. The business has a 50 day moving average price of $1.20 and a two-hundred day moving average price of $1.26.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last released its earnings results on Wednesday, August 13th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.05. Equities analysts expect that Allogene Therapeutics will post -1.28 EPS for the current fiscal year.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.